Last reviewed · How we verify

Ketamine plus Midazolam

Zagazig University · FDA-approved active Small molecule Quality 5/100

Ketamine plus Midazolam is a Small molecule drug developed by Zagazig University. It is currently FDA-approved.

At a glance

Generic nameKetamine plus Midazolam
SponsorZagazig University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ketamine plus Midazolam

What is Ketamine plus Midazolam?

Ketamine plus Midazolam is a Small molecule drug developed by Zagazig University.

Who makes Ketamine plus Midazolam?

Ketamine plus Midazolam is developed and marketed by Zagazig University (see full Zagazig University pipeline at /company/zagazig-university).

What development phase is Ketamine plus Midazolam in?

Ketamine plus Midazolam is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing